Extravasation of chemotherapeutic agents: Prevention and therapy;Paravasation von zytostatika: Prävention und Therapie

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 1-2, 2005, Pages 33-37

  Jordan, K ^a   Grothe, W ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIDOTE; ANTINEOPLASTIC AGENT; CISPLATIN; DACTINOMYCIN; DAUNORUBICIN; DIMETHYL SULFOXIDE; DOXORUBICIN; EPIRUBICIN; HYALURONIDASE; IDARUBICIN; MITOMYCIN C; MITOXANTRONE; RAZOXANE; STEROID;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; DIFFERENTIAL DIAGNOSIS; EXTRAVASATION; HUMAN; NONHUMAN; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; DIAGNOSIS, DIFFERENTIAL; DIMETHYL SULFOXIDE; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; IATROGENIC DISEASE; PEPTIDE HYDROLASES; RAZOXANE; RISK FACTORS; THIOSULFATES; TIME FACTORS;

EID: 11844296023     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837372     Document Type: Article

References (15)

1. Bertelli G, Gozza A, Forno GB, Vidilli MG, Silvestro S, Dini D. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851-2855
2. Berdel WE, Dempke W, Büchele T, Schmoll HJ. Prävention und Therapie von Paravasaten. 3nd ed (Hrsg). Berlin: Springer Verlag, In: Schmoll HJ, Höffken K, Possinger K, editors. Kompendium internistische Onkologie. 1999: 1689-1701
3. Bos AM, van der Graaf WT, Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and Dexrazoxane. Acta Oncologica 2001; 40: 541-542
4. Bozkurt AK, Uzel B, Akman C, Ozguroglu M, Molinas Mandel N. Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol 2003; 26: 121-123
5. Cicchetti S, Jemec B, Gault DT. Two case reports of vinorelbine extravasation: Management and review of literature. Tumori 2000; 86: 289-292
6. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4: 41-60
7. El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, Abbas J. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 2004; 5: 320-321
8. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hematooncological therapies. Ann Oncol 2004; 15: 858-862
9. Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg 2003; 37: 174-175
10. Köstering H, Nagel GA. Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 1980; 6: 317-320
11. Langer SW, Sehested M, Buhl Jensen P. Dexrazoxane is a potent and a specific inhibitor of anthracycline-induced subcutaneous lesions in mice. Ann Oncol 2000; 12: 405-410
12. Mader I, Fürst-Weger PR, Mader RM, Semenitz EI, Terkola R. Paravasation von Zytostatika. Wien: Springer Verlag, 2002
13. Olver IN, Aisner J, Hament A. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6: 1732-1735
14. Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11: 270-277
15. Van Sloten HK. Treatment of anthracycline extravasation - recommendations for practice. J Clin Oncol 1987; 5: 1705-1711